Summary Malotilate (diisopropyl,1 ,3-dithiol-2-ylidenemalonate, MT) is clinically used as a hepatoprotective agent. Because we noticed that MT induced the differentiation of cultured vascular endothelial cells, we have examined its effects on lung metastasis of the highly metastatic rat mammary carcinoma c-SST-2. MT was orally administered to syngeneic SHR rats from 7 days before or after s.c. inoculation of c-SST-2 cells to the end of the experiments. In the MT-treated rats, pulmonary metastasis was markedly suppressed compared with the non-treated rats. In the rats treated with MT for 19 days after i.v. inoculation of c-SST-2 cells, lung metastasis was also significantly suppressed. An in vitro invasion assay using a rat lung endothelial (RLE) cell monolayer revealed that pretreatment of the RLE cells with MT, but not c-SST-2 cells, significantly reduced the invasion of the RLE monolayer by c-SST-2 cells. An in vitro vascular permeability assay demonstrated that MT prevented the increase in permeability of the RLE monolayer by serum starvation. On the other hand, in vivo and in vitro growth, gelatinase production and adhesion to the RLE cell monolayer of c-SST-2 cells were not affected by MT treatment. These findings suggest that MT suppressed tumour metastasis by intensifying the cell-to-cell contact of endothelial cells, thus preventing tumour cells from invading vascular endothelium.
Most malignant tumour cells are capable of metastasizing to distant organs. This property of the malignant cells is responsible for most human cancer deaths, despite advances in surgery, radiotherapy and chemotherapy. Prevention of cancer metastasis is therefore a major objective of cancer research. The metastatic process of cancer is a series of sequential steps in which tumour cells are released from the primary tumour and disseminate to distant organs, where they proliferate to form new tumour foci (Poste and Fidler, 1980; Liotta, 1988; Nicolson, 1988) . Interactions of malignant cells with endothelial cells or subendothelial basement membrane play an important role in the establishment of blood-borne metastasis (Nicolson, 1989; Pauli et al, 1990) . The malignant cells meet with endothelium when they intra-or extravasate. In case of intra-or extravasation, tumour cells have to invade the endothelial cell monolayer and subendothelial basement membrane (Nicolson, 1982; Liotta, 1986) . In a sense, endothelium acts as a fort to blood-borne metastasis. In fact, peptides or antibodies that are able to block the adhesion of tumour cells to endothelium inhibit metastasis by rodent cancer cells (Humphries et al, 1986; Iwamoto et al, 1987; Saiki et al, 1989; Fujita et al, 1992) . The repression of matrix degradative activity by proteinase inhibitors, such as tissue inhibitor of matrix metalloproteinase (TIMP) , plasminogen activator inhibitor (PAI), urinary trypsin inhibitor and so on, lead a decrease in metastasis and in vitro invasion of reconstituted basement membrane by metastatic tumour cells (Schultz et al, 1988; Alvarez et al, 1990; Khokha, 1994; Kobayashi et al, 1995; Mueller et al, 1995) . In addition, the ability of tumour cells to induce retraction of the endothelial cell monolayer is one of the most important properties in intra-or extravasation. A drug that prevents tumour cells from inducing retraction of the endothelial cell layer is also a good candidate for an antimetastatic agent.
Malotilate (MT) , diisopropyl-1,3-dithiol-2-ylidenemalonate (Mr 288.38) , is in clinical use as a hepatoprotective agent. It has already been demonstrated in experiments using animal models that MT protects the liver against acute and chronic injuries induced by toxins and reduces hepatic fibrosis (Kato and Sugimoto, 1982; Nokata et al, 1985; Ryle and Dumont, 1987) . MT is known to increase RNA and protein synthesis by hepatocytes (Imaizumi, 1982a and b; Wakasugi and Tomikawa, 1987) . Furthermore, it also modifies the functions of endothelial cells, fibroblasts or macrophages (Ryle and Dumont, 1987; Zijlstra et al, 1989; Sunada et al, 1993) . For example, it was observed recently that MT with phosphoascorbic acid was effective for maintaining the cobblestone-shape monolayer of cultured bovine aortic endothelial cells for a long time and it developed various junctional apparates (Sunada et al, 1993) . This observation led us to speculate on the protective effects of MT on the retraction of the endothelial monolayer by tumour cells. Therefore, we examined its possible inhibitory effects on the haematogenous metastasis of a highly metastatic rat mammary carcinoma. Animals SHR rats were obtained from Nippon Rat (Urawa, Japan). Female SHR rats aged 7-10 weeks were used throughout the experiments.
Tumour cells and rat endothelial cells
The tumour cell line c-SST-2 was established from a mammary adenocarcinoma spontaneously developed in an SHR rat (Hamada et al, 1988) . The c-SST-2 cells possessed highly metastatic potential to lungs in syngeneic rats after s.c. or i.v. injection. This cell line was grown on tissue culture dishes in Eagle's minimum essential medium (MEM) supplemented with 7% fetal bovine serum (FBS). Rat lung endothelial (RLE) cells were kindly provided by Dr GL Nicolson (MD Anderson Cancer Center, Houston, TX, USA) (Nakajima et al, 1989) . RLE cells were grown on gelatincoated tissue culture dishes in Dulbecco's modified MEM (DME) supplemented with 10% FBS (ENDO medium).
Inoculation of c-SST-2 cells and administration of malotilate
MT was dissolved to be a 6% or 3% solution with 1% gum arabic solution. Three hundred milligrams or 150 mg kg-' body weight or 1% gum arabic solution as vehicle control was given daily orally by means of Nelaton's catheter. For spontaneous metastasis assay, MT administration was started 7 days before or after s.c. inoculation with c-SST-2 cells (1 x 105 or 2 x 105) in the right back of syngeneic SHR rats and continued until the 28th or 30th day after the tumour inoculation. The mean tumour diameter of individual tumours, measured with callipers, was calculated from measurements of two planes at right angles. The rats were killed on the 35th day after the tumour inoculation and examined for metastases. Pulmonary metastases were estimated by macroscopically counting the numbers of metastatic nodules on the lung surface after fixation of lungs with Bouin's solution.
For experimental metastasis assay, SHR rats were orally administered MT (300 mg kg-' day-') for 7 days before and for 19 days after i.v. injection with c-SST-2 cells (5 x 104) into the tail vein. Twenty days after the tumour injection, the rats were killed and examined for metastases. Pulmonary metastatic nodules were counted as described above. Assay for in vitro growth of c-SST-2 and RLE cells c-SST-2 and RLE cells (1 x 106 per dish) were seeded on 100-mm tissue culture dishes in DME supplemented with 7% FBS and then treated with various concentrations of MT for 24 h. The cells (5 x 104 per well) pretreated with or without MT were transferred into 24-well plates. The cells were chronologically harvested and counted with a haemocytometer. In another experiment, the cells (5 x 104 per well) were seeded on 24-well plates in DME supplemented with 7% FBS, and simultaneously various concentrations of MT was added into each well. The cells were chronologically harvested and counted with a haemocytometer.
Assay for in vitro chemoinvasion of reconstituted basement membrane, Matrigel, by c-SST-2 cells
In vitro tumour cell invasion was assayed according to the method reported by Albini et al (1987) overnight. The Matrigel was washed twice with 100 g1 of DME and incubated with DME for 1 h at room temperature. Before the assay, the medium in the upper compartment of the Transwell chamber was removed, and then 600 ,ul of medium conditioned with skin fibroblasts from a new-born SHR rat was placed into the lower compartment of the Transwell chamber as a chemoattractant, and 50 g1 of c-SST-2 cell suspension (4 x I05 ml-) in DME supplemented
British Joumal of Cancer (1998) 1374 H Nagayasu et al 30 min and then rinsed three times with DME. Labelled tumour cells were suspended in DME containing 1% bovine serum albumin (BSA) at a density of 2 x 105 cells ml-'. The cell suspensions (0.5 ml per well) were placed in RLE culture plate prepared as above. After 10, 20, 30, 60 and 120 min of incubation in a carbon dioxide incubator, the cultures in triplicate cells were washed three times with DME; the attached cells were lysed in 1% Triton X-100 at 37°C. The fluorescence intensity of the lysates was measured under excitation at 490 nm and emission at 520 nm using a spectrofluorimeter (Model LS 50B, Perkin Elmer, Buckinghamshire, UK). Adhesion rates were evaluated as % [fluorescence intensity of lysates of attached cells/fluorescence intensity of lysates of initial seeded cells (1 x 105 labelled cells)] x 100.
Zymography for gelatinase of c-SST-2 cells Tumour cells (2 x 105 per well) were cultured on a 12-well tissue culture plate in DME supplemented with 7% FBS overnight. The culture was washed twice with DME and 1 ml of DME was added to each well. After a 24-h incubation, supematants were collected, centrifuged at 800 g for 10 min and recentrifuged at 20 000 g for 1 h. The serum-free samples were mixed with sample buffer at 2:1 and loaded on a sodium dodecyl sulphate (SDS)-gelatinembedded gel (0.75 mm thickness) prepared using previously published procedures (Nakajima et al, 1989) . Electrophoresis was carried out using Laemmli's method under cooling conditions (Laemmli, 1970) . After the electrophoresis, the gel was rinsed with 2.5% Triton X-100 in 50 mm Tris-HCl buffer (pH 7.5) containing 0.05% sodium azide on a rocker platform at room temperature for 1.5 h. The gel was incubated at 37°C for 24 h in 0.15 M sodium chloride, 1O mM calcium chloride and 50 mM Tris-HCl buffer (pH 7.5) containing sodium azide. After the incubation, the gel was stained with 0.05% Coomassie Blue R-250 in isopropanol-acetic acid-water (1:1:8), destained with isopropanol-acetic acid-water (1:1:8). Gelatinolytic enzymes were detected as transparent bands on the blue background of a Coomassie blue-stained slab gel. (600 gl) was also placed into the lower compartment of the chambers. After a 24-h incubation, the media in both compartments were removed and DME containing various concentrations of MT and 4% FBS were added into both compartments. The cultures were incubated for 24 h and then washed twice with DME. In the experiment under serum-starved conditions, fresh DME was placed into both the upper and the lower compartments of the chamber. As non-serum-starved control, DME supplemented with 4% FBS was placed instead of DME. In the experiment under coculture with tumour cells, c-SST-2 cells (500 cells per 0.1 ml of DME supplemented with 4% FBS) were overlayed onto the RLE monolayer and DME supplemented with 4% FBS was placed into the lower compartment. For assessment of permeability, 10 ,l of FITC-dextran (=70 kDa, 10 mg ml-', Sigma, St Louis, MO, USA) in DME was added into the upper compartment and the cultures were incubated for 6 h. The media in the lower compartments were transferred into a 96-well microtitre plate (100 gl per well)
for measuring fluorescence. Fluorescence intensity was measured using a spectrofluorimeter (Corona Electric, Hitachinaka, Japan) at 490 nm (excitation) and 530 nm (emission).
RESULTS

Inhibitory effects of malotilate on pulmonary metastasis of c-SST-2 cells
As shown in Table 1 , the numbers of pulmonary metastatic nodules and lung weight of the rats treated with malotilate (MT) were significantly reduced compared with those of the non-treated rats when c-SST-2 cells had been inoculated subcutaneously 7 days before MT administration. Next, we examined the effects of MT when it was administered after the establishment of a primary tumour. MT administration was started 7 days after the c-SST-2 cell inoculation when primary tumours had already developed ( Figure 2B ). Like the result from pretreatment of MT, pulmonary metastasis was significantly inhibited in the rats administered with MT compared with non-treated or vehicle control rats. Experimental pulmonary metastasis was also significantly reduced in the MT-treated rats (300 mg kg-1 day-') compared with the nontreated rats. On the other hand, when tumour cells had been s.c. inoculated, the tumour growth in primary sites was not affected by the treatment with MT (Figure 2 ).
Effects of malotilate on in vitro invasion of the rat lung endothelial cell monolayer and reconstituted basement membrane, Matrigel
When c-SST-2 cells were pretreated with MT for 24 h, their invasion of both RLE cell monolayer and Matrigel did not differ from that of the non-treated ( Figure 3B and C) . In contrast, when RLE cells were pretreated with MT for 24 h, the invasion of the RLE monolayer by c-SST-2 cells was markedly inhibited ( Figure 3A) . Effects of malotilate on the permeability of the rat lung endothelial cell monolayer
The permeability of the RLE monolayer increased by serum starvation when RLE cells seeded on the gelatin-coated membrane of Transwell reached confluence. Pretreatment of the RLE cell monolayer with more than 20 ng ml-' of MT for 24 h led to inhibition of the increase in the permeability by serum starvation to the permeability level of the non-serum-starved RLE monolayer ( Figure  4A ). The increase in the permeability of the RLE cell monolayer by co-culturing with c-SST-2 cells was also inhibited by pretreatment with MT ( Figure 4B ).
Effects of malotilate on in vitro growth, gelatinase production and adhesion to the rat lung endothelial cell monolayer by c-SST-2 and RLE cells
In vitro growth of c-SST-2 or RLE cells was not affected by pretreatment with MT for 24 h (data not shown). The adhesion of c-SST-2 cells to the RLE monolayer was not affected by the pretreatment of c-SST-2 cells or RLE cells with MT ( Figure 5A ). Furthermore, adhesion of c-SST-2 cells pretreated with malotilate to the RLE cell monolayer also pretreated with malotilate was examined in the presence of the same concentration of molotilate as the pretreatment. As shown in Figure 5B , the adhesion rate of c-SST-2 cells to the RLE monolayer was almost the same even if Malotilate was present during the adhesion assay. By zymographic analysis, 92-kDa, 67-kDa and 64-kDa enzymatic bands were detected in medium conditioned with c-SST-2 cells, and the production of these gelatinases was not changed by MT treatment (Figure 6 ). No gelatinolytic activity was detected in medium conditioned with RLE cells treated with or without MT.
DISCUSSION
We showed here that malotilate (MT), which has been used clinically for liver disease, in stimulating liver functions, demonstrated inhibitory action against pulmonary metastasis but not local growth of c-SST-2 rat mammary carcinoma cells. The treatment of c-SST-2 cells with MT did not modify their metastasis-associated properties, such as adhesion and invasion into the RLE endothelial cell monolayer or basement membrane, gelatinase production and migration activity. On the other hand, the in vitro invasion of the RLE monolayer by c-SST-2 cells was inhibited by treatment of RLE but not c-SST-2 cells with MT. Therefore, it seems that MT acts on endothelial cells but not on tumour cells to inhibit metastasis. The inhibitory effect of MT on the in vitro invasion of the RLE monolayer by c-SST-2 cells may be partly because MT prevents the retraction of the RLE monolayer, as MT treatment suppresses the increase in permeability of the RLE monolayer by serum starvation or co-culture with c-SST-2 cells. These findings suggest that MT acts on endothelial cells to intensify the cell adhesion among endothelial cells, which prevents c-SST-2 cells from penetrating through the endothelium. The inhibitory effect on the experimental metastasis was less than that on spontaneous metastasis. The difference in the effect between experimental metastasis and spontaneous metastasis systems may be caused by the following: (1) in i.v. inoculation of tumour cells, a large number of tumour cells may be circulated at a time, which provides more chances to extravasate endothelium; (2) in the spontaneous metastasis system, tumour cells need to twice penetrate the endothelium that blocks their way, whereas in the experimental metastasis system they need it only once. Thus, inhibitory effects of MT on metastasis may differ depending on inoculation routes of tumour cells.
The mechanism by which MT intensifies cell-cell adhesion among endothelial cells is not clear. It is reported that MT stimulates RNA and protein syntheses and glucose metabolism in the liver and the cultured hepatocyte (Imaizumi, 1982a and b; Wakasugi and Tomikawa, 1987) . It is also known that MT modulates the functions of various types of cells other than hepatocytes (Ryle and Dumont, 1987; Zijlstra et al, 1989; Sunada et al, 1993) . In fact, we have observed electron microscopically that MT promoted the development of cell-cell adhesion apparates, such as gap junctions and desmosomes (unpublished data). Further, we have data indicating that the expression of connexin 43 proteins, which are components of gap junctions, is enhanced in RLE cells by MT treatment (unpublished data). Sunada et al (1993) also reported that MT preserved the cobblestone-shaped cell monolayer of bovine endothelial cells for a long-term culture and promoted the formation of adherence junctions and gap junctions between endothelial cells. Therefore, we speculate that MT may stimulate endothelial cells to synthesize proteins, including the molecules involved in homophilic cell-cell adhesion.
Regarding the inhibitory effect of MT on increased permeability of the RLE monolayer caused by co-culture with tumour cells, we also need to consider another possibility besides the intensifying effect of MT on cell adhesion among endothelial cells. Enhanced permeability of the endothelial cell monolayer by co-culture with tumour cells may be due to endothelial cell retraction mediated by the interaction of endothelial cells with the tumour cells. Endothelial cell retraction is known to be induced by soluble factors or direct adhesion of other types of cells from which intracellular signals are transduced to induce morphological changes of cells and to reduce adhesiveness among endothelial cells (Tang et al, 1993a and b) . Therefore, the possibility remains that MT may block the signal transduction involved in endothelial cell retraction, besides intensification of adhesiveness among endothelial cells.
There are some reports that the blockage of the interaction between tumour cells and endothelium in target organs leads to the inhibition of metastasis in animal models. For example, anti-adhesive pepetides based on the amino acid sequence RGDS or YIGSR are able to block the adhesion of tumour cells to subendothelial basement membrane components, resulting in anti-metastatic effects (Humphries et al, 1986; Iwamoto et al, 1987; Saiki et al, 1989) . Antibodies to integrins are also known to have similar metastasis-inhibitory effects (Fujita et al, 1992; Kawaguchi et al, 1992) . One of the mechanisms for the anti-metastatic action of protease inhibitors, such as tissue inhibitor of metalloproteinase (TIMP) and plasminogen activator inhibitor (PAI), is thought to prevent intra-or extravasation of tumour cells by inhibition of the degradation of the basement membrane (Schultz et al, 1988; Cajot et al, 1990; Albini et al, 1991; Khokha et al, 1992) . Anti-angiogenic agents may also be recognized as a blocker of the tumour cell-endothelium interaction to suppress the growth of metastatic foci (Ingber et al, 1990; O'Reilly et al, 1994) . Compared with these anti-metastatic agents, MT is unique for its mechanism of action as it enhances the defensive ability of endothelial cells against the penetration by metastatic tumour cells but does not modify the offensive properties of tumour cells per se to establish metastases. As MT did not have any toxicity to SHR rats at the doses used here, it may be potentially useful in the prevention of cancer metastasis, probably being more effective in anti-metastasis when in combination with other therapeutic drugs. However, further study is needed to examine in detail the mechanisms of the intensification of adhesion among endothelial cells and to examine the influence on the other host cells, such as the immune cells.
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